Arterial Occlusive Disease | Association of serum cystatin C level with coronary atherosclerotic plaque burden: a comprehensive analysis of observational studies and genetic study | springermedicine.com

Springer Medicine

Top

BMC Cardiovascular Disorders

Published in:

Open Access 01-12-2023 | Arterial Occlusive Disease | Research

Association of serum cystatin C level with coronary atherosclerotic plaque burden: a comprehensive analysis of observational studies and genetic study

Authors: Jun Chen, Jiayi Shen, Yuesong Pan, Jing Jing, Yongjun Wang, Tiemin Wei, Lingchun Lyu

Published in: BMC Cardiovascular Disorders | Issue 1/2023

Login to get access

Abstract

Background and Aims

Epidemiological studies show that high circulating cystatin C is associated with risk of cardiovascular disease (CVD), independent of creatinine-based renal function measurements. However, the relationship between serum cystatin C level and coronary atherosclerotic plaque burden is limited. We aimed to evaluate the relationship between circulating cystatin C and coronary atherosclerotic plaque burden.

Methods

This study was a cross-sectional study based on China community population. Measurements of plaque burden were based on the segment-involvement score (SIS) and segment stenosis score (SSS), which derived from the Coronary Artery Tree Model Depicting Coronary Artery Plaque Scores. Logistic regression model was used to demonstrate the association between cystatin C level and coronary artery plaque burden. Mendelian randomization (MR) analyses were conducted to assess the causal effect of cystatin C level on coronary atherosclerosis risk.

Results

A total of 3,043 objects were included in the present study. The odds risks (OR) of severe plaque burden in the highest serum cystatin C levels (OR: 2.50; Cl:1.59–3.91; P < 0.001) and medium-level cystatin C levels (OR: 1.86; 95% Cl: 1.21–2.88; P = 0.005) were significantly higher after fulled adjusted confounders compared with the lowest levels of serum cystatin C by SSS. The MR analysis showed that genetic predicted cystatin C levels was associated with an increased risk of coronary atherosclerosis (OR, 1.004; 95% CI, 1.002–1.006, P < 0.001) .

Conclusion

Elevated serum cystatin C levels were associated with coronary atherosclerotic plaque burden. Cystatin C levels had a causal effect on an increased risk of coronary atherosclerosis at the genetic level.

What is already known on this topic?

Coronary artery disease is currently the most common cardiovascular disease and the leading global cause of mortality. Previous studies reported that higher serum cystatin C levels were associated with an increased risk for future cardiovascular events, independent of the normal creatinine levels or estimated glomerular filtration rate (eGFR) values. The presence of high-risk coronary atherosclerotic plaque burden is associated with increased risk of cardiovascular events. However, the association between serum cystatin C and coronary atherosclerotic plaque burden is not very clear.

What this study adds?

Our study demonstrated that the elevated serum cystatin C levels were associated with coronary atherosclerotic plaque burden. In addition, we found that serum cystatin C levels had a causal effect on an increased risk of coronary atherosclerosis at the genetic level.

How this study might affect research, practice or policy?

Current research finds that serum cystatin C levels were associated with coronary atherosclerosis. The metabolic pathway of cystatin C could be a target for new therapies against CAD.

Available only for authorised users

1.

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34(38)2949–3003 2013.

2.

Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23. https://doi.org/10.1002/jcp.28350.CrossRefPubMed

3.

Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481–8. https://doi.org/10.1161/CIRCULATIONAHA.105.537878.CrossRefPubMed

4.

Gerbaud E, Weisz G, Tanaka A, Luu R, Osman H, Baldwin G, Coste P, Cognet L, Waxman S, Zheng H, et al. Plaque burden can be assessed using intravascular optical coherence tomography and a dedicated automated processing algorithm: a comparison study with intravascular ultrasound. Eur Heart J Cardiovasc Imaging. 2020;21(6):640–52.CrossRefPubMed

5.

Arbab-Zadeh A, Fuster V. The risk continuum of atherosclerosis and its implications for defining CHD by coronary angiography. J Am Coll Cardiol. 2016;68(22):2467–78.CrossRefPubMed

6.

Knight EL, Verhave JC, Spiegelman D, et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65(4):1416–21.CrossRefPubMed

7.

Palanca A, Castelblanco E, Betriu A, Perpinan H, Soldevila B, Valdivielso JM, Bermudez-Lopez M, Puig-Jove C, Puig-Domingo M, Groop PH, et al. Subclinical atherosclerosis burden predicts cardiovascular events in individuals with diabetes and chronic kidney disease. Cardiovasc Diabetol. 2019;18(1):93.CrossRefPubMedPubMedCentral

8.

Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49–57.CrossRefPubMed

9.

Motoyama S, Ito H, Sarai M, et al. Plaque characterization by coronary computed tomography angiography and the likelihood of acute coronary events in mid-term follow-up. J Am Coll Cardiol. 2015;66:337–46.CrossRefPubMed

10.

Park H-B, Heo R, ó Hartaigh B, et al. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. J Am Col Cardiol Img. 2015;8:1–10.CrossRef

11.

van der Laan SW, Fall T, Soumare A, Teumer A, Sedaghat S, Baumert J, Zabaneh D, van Setten J, Isgum I, Galesloot TE, et al. Cystatin C and Cardiovascular Disease: a mendelian randomization study. J Am Coll Cardiol. 2016;68(9):934–45.CrossRefPubMedPubMedCentral

12.

Hoke M, Amighi J, Mlekusch W, Schlager O, Exner M, Sabeti S, Dick P, Koppensteiner R, Minar E, Rumpold H, et al. Cystatin C and the risk for cardiovascular events in patients with asymptomatic carotid atherosclerosis. Stroke. 2010;41(4):674–9.CrossRefPubMed

13.

Luo J, Wang LP, Hu HF, Zhang L, Li YL, Ai LM, Mu HY, Kun-Wang. Cystatin C and cardiovascular or all-cause mortality risk in the general population: a meta-analysis. Clin Chim Acta. 2015;450:39–45. https://doi.org/10.1016/j.cca.2015.07.016.CrossRefPubMed

14.

Garcia-Carretero R, Vigil-Medina L, Barquero-Perez O, Goya-Esteban R, Mora-Jimenez I, Soguero-Ruiz C, Ramos-Lopez J. Cystatin C as a predictor of cardiovascular outcomes in a hypertensive population. J Hum Hypertens. 2017;31(12):801–7. https://doi.org/10.1038/jhh.2017.68.CrossRefPubMed

15.

Pan Y, Jing J, Cai X, et al. PolyvasculaR evaluation for cognitive impairment and vaScular events (PRECISE)-a population-based prospective cohort study: rationale, design and baseline participant characteristics. Stroke Vasc Neurol. 2020. https://doi.org/10.1136/svn-2020-000411.CrossRefPubMedPubMedCentral

16.

Min JK, Shaw LJ, Devereux RB, Okin PM, Weinsaft JW, Russo DJ, Lippolis NJ, Berman DS, Callister TQ. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol. 2007;50(12):1161–70.CrossRefPubMed

17.

Bittencourt SM, Hulten PE, et al. Prognostic value of nonobstructive and obstructive coronary artery disease detected by coronary computed tomography angiography to identify cardiovascular events. Circ: Cardiovasc Imag. 2014;7:282–91.

18.

Min JK, Shaw LJ, et al. Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. JACC. 2007;50:1161–70.CrossRefPubMed

19.

Newman DJ, Cystatin C. Ann Clin Biochem. 2002;39(Pt 2):89–104. https://doi.org/10.1258/0004563021901847.CrossRefPubMed

20.

Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int. 2004;65:1416–21.CrossRefPubMed

21.

Doganer YC, Aydogan U, Aydogdu A, Aparci M, Akbulut H, Nerkiz P, Turker T, Cayci T, Barcin C, Saglam K. Relationship of cystatin C with coronary artery disease and its severity. Coron Artery Dis. 2013;24(2):119–26.CrossRefPubMed

22.

Patel D, Ahmad S, Silverman A, Lindsay J. Effect of cystatin C levels on angiographic atherosclerosis progression and events among postmenopausal women with angiographically decompensated coronary artery disease (from the Women’s angiographic vitamin and estrogen [WAVE] study). Am J Cardiol. 2013;111(12):1681–7.CrossRefPubMed

23.

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95. https://doi.org/10.1056/NEJMra043430.CrossRefPubMed

24.

Shlipak MG, Katz R, Cushman M, Sarnak MJ, Stehman-Breen C, Psaty BM, Siscovick D, Tracy RP, Newman A, Fried L. Cystatin-C and inflammatory markers in the ambulatory elderly. Am J Med. 2005;118(12):1416. https://doi.org/10.1016/j.amjmed.2005.07.060.CrossRefPubMed

25.

Gao D, Shao J, Jin W, Xia X, Qu Y. Correlations of serum cystatin C and hs-CRP with vascular endothelial cell injury in patients with systemic lupus erythematosus. Panminerva Med. 2018;60(4):151–5. https://doi.org/10.23736/S0031-0808.18.03466-3.CrossRefPubMed

26.

Yamashita H, Nishino T, Obata Y, Nakazato M, Inoue K, Furusu A, Takamura N, Maeda T, Ozono Y, Kohno S. Association between cystatin C and arteriosclerosis in the absence of chronic kidney disease. J Atheroscler Thromb. 2013;20(6):548–56. https://doi.org/10.5551/jat.13193.CrossRefPubMed

27.

Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998;102(3):576–83.CrossRefPubMedPubMedCentral

28.

Sukhova GK, Zhang Y, Pan JH, Wada Y, Yamamoto T, Naito M, Kodama T, Tsimikas S, Witztum JL, Lu ML, Sakara Y, Chin MT, Libby P, Shi GP. Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;111:897–906.CrossRefPubMedPubMedCentral

29.

Evangelopoulos AA, Vallianou NG, Bountziouka V, et al. Association between serum cystatin C, monocytes and other inflammatory markers. Intern Med J. 2012;42(5):517–22.CrossRefPubMed

30.

Ganda A, Magnusson M, Yvan-Charvet L, Hedblad B, Engström G, Ai D, Wang TJ, Gerszten RE, Melander O, Tall AR. Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation. 2013;127(9):988–96. https://doi.org/10.1161/CIRCULATIONAHA.112.000682.CrossRefPubMedPubMedCentral

31.

Patel PC, Ayers CR, Murphy SA, Peshock R, Khera A, de Lemos JA, Balko JA, Gupta S, Mammen PP, Drazner MH, et al. Association of cystatin C with left ventricular structure and function: the Dallas Heart Study. Circ Heart Fail. 2009;2(2):98–104.CrossRefPubMed

32.

Xie L, Terrand J, Xu B, Tsaprailis G, Boyer J, Chen QM. Cystatin C increases in cardiac injury: a role in extracellular matrix protein modulation. Cardiovasc Res. 2010;87(4):628–35. https://doi.org/10.1093/cvr/cvq138.CrossRefPubMedPubMedCentral

33.

Sinnott-Armstrong N, Tanigawa Y, Amar D, Mars N, Benner C, Aguirre M, Venkataraman GR, Wainberg M, Ollila HM, Kiiskinen T, Havulinna AS, Pirruccello JP, Qian J, Shcherbina A, FinnGen, Rodriguez F, Assimes TL, Agarwala V, Tibshirani R, Hastie T, Ripatti S, Pritchard JK, Daly MJ, Rivas MA. Author Correction: Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet. 2021;53(11):1622. https://doi.org/10.1038/s41588-021-00956-2. Erratum for: Nat Genet. 2021;53(2):185–194. PMID: 34608296.

Title: Association of serum cystatin C level with coronary atherosclerotic plaque burden: a comprehensive analysis of observational studies and genetic study
Authors: Jun Chen
Jiayi Shen
Yuesong Pan
Jing Jing
Yongjun Wang
Tiemin Wei
Lingchun Lyu
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Arterial Occlusive Disease
Arterial Diseases
Published in: BMC Cardiovascular Disorders / Issue 1/2023
Electronic ISSN: 1471-2261
DOI: https://doi.org/10.1186/s12872-023-03506-2

Home
Congress Coverage
Clinical Collections
- Advances in Alzheimer’s
About Springer Medicine
Key Specialties